東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Science as an element of innovation ...

Vandaie, Ramin.

FindBook

Google Book

Amazon

博客來

Science as an element of innovation strategy: Evidence from the pharmaceutical industry.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Science as an element of innovation strategy: Evidence from the pharmaceutical industry./
作者:	Vandaie, Ramin.
面頁冊數:	105 p.
附註:	Source: Dissertation Abstracts International, Volume: 75-01(E), Section: A.
Contained By:	Dissertation Abstracts International75-01A(E).
標題:	Business Administration, Management. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3596366
ISBN:	9781303428241

Science as an element of innovation strategy: Evidence from the pharmaceutical industry.
Vandaie, Ramin.

Science as an element of innovation strategy: Evidence from the pharmaceutical industry. - 105 p.

Source: Dissertation Abstracts International, Volume: 75-01(E), Section: A.

Thesis (Ph.D.)--University of Minnesota, 2013.

An extensive literature has informed us that science matters for firm innovation. But the primary question of interest to strategy research in this regard has remained unanswered: what drives the differences among firms in how tightly they couple science with the other elements of their innovation strategy, and what implications do such differences hold for firms' innovativeness. This study takes a first step to answer this question by focusing on the relationship between science and R&D; alliances representing key elements of any firm's innovation strategy. Specifically, I conceptualize absorptive capacity as a latent construct that mediates the link between science productivity and the extent of new R&D; alliance formations. I then hypothesize that two sets of factors (scientist-based and firm-based) moderate the strength of the baseline relationship by impacting either the resulting absorptive capacity for a given level of science productivity or the substitutability of absorptive capacity as a driver of new R&D; alliance formations. I then move on to explore the role of absorptive capacity at the time of forming new R&D; alliances on the long-term benefits of those alliance for the firm's innovative output. The results of the analysis of a longitudinal database on 216 publicly-traded pharmaceutical companies in US between 1990 and 2009 provide general support for the proposed theoretical framework of the study.

ISBN: 9781303428241Subjects--Topical Terms:

626628
Business Administration, Management.

Science as an element of innovation strategy: Evidence from the pharmaceutical industry.
LDR:02318nam a2200277 4500 001 1959554
005 20140520124326.5
008 150210s2013 ||||||||||||||||| ||eng d
020 $a 9781303428241
035 $a (MiAaPQ)AAI3596366
035 $a AAI3596366
040 $a MiAaPQ $c MiAaPQ
100 1 $a Vandaie, Ramin. $3 2095008
245 1 0 $a Science as an element of innovation strategy: Evidence from the pharmaceutical industry.
300 $a 105 p.
500 $a Source: Dissertation Abstracts International, Volume: 75-01(E), Section: A.
500 $a Adviser: Aks Zaheer.
502 $a Thesis (Ph.D.)--University of Minnesota, 2013.
520 $a An extensive literature has informed us that science matters for firm innovation. But the primary question of interest to strategy research in this regard has remained unanswered: what drives the differences among firms in how tightly they couple science with the other elements of their innovation strategy, and what implications do such differences hold for firms' innovativeness. This study takes a first step to answer this question by focusing on the relationship between science and R&D; alliances representing key elements of any firm's innovation strategy. Specifically, I conceptualize absorptive capacity as a latent construct that mediates the link between science productivity and the extent of new R&D; alliance formations. I then hypothesize that two sets of factors (scientist-based and firm-based) moderate the strength of the baseline relationship by impacting either the resulting absorptive capacity for a given level of science productivity or the substitutability of absorptive capacity as a driver of new R&D; alliance formations. I then move on to explore the role of absorptive capacity at the time of forming new R&D; alliances on the long-term benefits of those alliance for the firm's innovative output. The results of the analysis of a longitudinal database on 216 publicly-traded pharmaceutical companies in US between 1990 and 2009 provide general support for the proposed theoretical framework of the study.
590 $a School code: 0130.
650 4 $a Business Administration, Management. $3 626628
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0454
690 $a 0572
710 2 $a University of Minnesota. $b Business Administration. $3 1022265
773 0 $t Dissertation Abstracts International $g 75-01A(E).
790 $a 0130
791 $a Ph.D.
792 $a 2013
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3596366